RCUS: Casdatifan and quemliclustat lead a robust pipeline with strong late-stage data and major market potential

A diverse late-stage oncology and immunology pipeline is highlighted by casdatifan, which shows superior efficacy and safety in RCC compared to current standards, and quemliclustat, which could transform 1L pancreatic cancer treatment. Multiple Phase 3 trials and key data readouts are expected in l…